Multiple myeloma (MM), a terminally differentiated B-cell malignancy, is characterized by excess bone marrow (BM) plasma cells and immunosuppression. At present, the role of B-cell subsets in the MM-related immune suppressive BM microenvironment is not fully characterized. Regulatory B cells (Bregs), a small B-cell subset, can regulate immune responses via stimulation of anti-inflammatory cytokine interleukin 10 (IL10), and modulation of CD4 + T-cell activation and differentiation. 1 In both animal models and man, Bregs in peripheral blood (PB) have been identified in the setting of autoimmune diseases, chronic inflammatory conditions and graft vs host disease postallogeneic transplantation. 2, 3 At present, the role of Bregs in cancers, including MM, has not been fully studied. 4 Here we phenotypically define Bregs in MM and examine their role in mediating immunosuppression, which is a hallmark of this disease. The detailed methods are described in the Supplementary Material.
In Figure S2a) . In contrast, the PB-derived Breg subset is not completely separated from the rest of PB mononuclear cells (PBMCs) as a detached population, consistent with previous reports where only blood samples from different autoimmune diseases were studied. [5] [6] [7] Importantly, this is the first report that CD19
high Bregs are easily distinguished from other cells in the BM, but not PB, compartments from the same MM patient.
To determine the relationship between Bregs and disease status in MM, we next determined frequencies of Bregs within CD19 + B cells in MM at diagnosis, during maintenance treatment after MM response, and at time of relapse, in BM and PB samples.
Frequencies of Bregs in CD19
+ B cells in BM are significantly higher compared with PB from NDMM (14.04 ± 1.77% vs 4.78 ± 0.98%; P o0.0005; Figure 1b) . BM-derived Bregs within CD19 + B cells are significantly higher in patients with NDMM than in those on maintenance therapy after response (14.04 ± 1.77% vs 1.48 ± 0.83%, respectively, P o 0.0001, n = 10 for each group; Figure 1b) . In a similar fashion, frequencies of PB-derived Bregs were significantly altered (5.04 ± 1.97% vs 1.95 ± 0.86%) in NDMM vs patients on maintenance therapy after response (P o0.02). In contrast to prior studies examining human Bregs circulating in PB and murine Bregs in spleens, 7 the current report shows that immunosuppressive Bregs represent a distinct subset in MM BM. MM cells in the BM 10 promote survival by inhibiting apoptosis of Bregs, which in turn mediates immunosuppression by production of IL10 and alternative mechanisms. 11 Importantly, Bregs in the BM are upregulated at time of diagnosis and decreased at time of response and maintenance therapy. At time of relapse, CD19 + B cells, including Bregs, are too low to be detected. 12 This is due in part to severe acquired immunodeficiency accompanying with a progressive depletion of lymphocytes, including CD19 + B cells, during relapse.
Finally, in the current era of immunotherapy for MM, 13, 14 we here demonstrate that MM Bregs can abrogate NK cell-mediated ADCC against MM cells, further supporting Bregs as a novel cellular target of future therapeutics. 15 Our current study also Letter to the Editor suggests that novel therapies targeting Bregs may enhance ADCC activity and MM cytotoxicity triggered by anti-SLAMF7, -CD38 and monoclonal antibodies against other MM target antigens.
In summary, our data show that MM BM Bregs confer an immunosuppressive BM microenvironment, which may in turn impact therapeutic response and disease outcome. Further understanding these unique B cell subsets will provide the rationale for targeting Bregs as a novel immuno-therapeutic strategy in MM.
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